VYNE Therapeutics (VYNE) AI Stock Analysis

• Market Cap: $28.59M
• Dividend Yield: N/A
• Average Volume (3M): 76.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: 18.16%
• EPS Growth: 86.65%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.93
• Shares Outstanding: 15,209,862
• 10 Day Avg. Volume: 56,259
• 30 Day Avg. Volume: 76,086
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 61.09
• Price to Cash Flow (P/CF): -0.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.19
• Price Target Upside: 229.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

VYNE Therapeutics' overall stock score is impacted by significant financial difficulties, including persistent losses and negative cash flows. The technical indicators show negative momentum, while valuation metrics are concerning with a negative P/E ratio. Despite some positive corporate events, these do not offset the financial and technical challenges.

Positive Factors

Clinical Trials

The Phase IIb study evaluating repibresib gel has demonstrated rapid and meaningful clinical benefit, as well as a favorable safety profile with limited systemic exposure in earlier trials.

Financial Stability

VYNE ended FY24 with $61.5M in cash and equivalents which the company is guiding as sufficient to fund operations into 2H26.

Negative Factors

Market Competition

Psoriasis is a relatively mature market and looks like a well-suited steppingstone for VYN202 to demonstrate clinical PoC.

VYNE Therapeutics Business Overview & Revenue Model

Company Description

VYNE Therapeutics (VYNE) is a biopharmaceutical company focused on developing and commercializing innovative therapies in dermatology and other disease areas. The company is dedicated to advancing its proprietary pipeline of treatments targeting inflammatory and immunomodulatory conditions. VYNE's core products include topical treatments for dermatological conditions such as acne and rosacea, with a focus on delivering effective and patient-friendly solutions.

How the Company Makes Money

VYNE Therapeutics generates revenue primarily through the sale of its dermatological products. The company markets and sells its proprietary topical treatments to healthcare providers, pharmacies, and directly to consumers. Additionally, VYNE may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop or distribute its therapies, which can provide additional revenue streams. The company's earnings are driven by product sales, potential milestone payments, and royalties from licensing agreements.

VYNE Therapeutics Financial Statement Overview

Summary

VYNE Therapeutics faces significant financial challenges with persistent losses and cash flow issues. The balance sheet is relatively strong with low leverage, but ongoing unprofitability and negative cash flows raise concerns about financial sustainability. The company's financial position is undermined by the biotechnology industry's volatility.

Income Statement

VYNE Therapeutics has shown a significant decline in revenue over recent years, with a steep drop from 2020 to 2024. The gross profit margin is positive, but the company is facing substantial operating losses as evidenced by negative EBIT and EBITDA margins. The net profit margin is also significantly negative, highlighting persistent unprofitability. These metrics indicate challenges in achieving revenue growth and controlling costs.

Balance Sheet

The company has maintained a healthy equity position with a low debt-to-equity ratio, suggesting limited leverage risk. However, there is a consistent decrease in stockholders' equity over the last few years. The equity ratio is relatively strong, indicating a stable asset base primarily funded by equity. Despite these strengths, profitability remains an issue.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn, which is a concern for sustainability. Free cash flow has been negative, with limited growth in free cash flow, suggesting cash management challenges. The company has relied on financing activities to supplement cash needs, which could pose future risks if access to capital markets becomes constrained.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
493.00K	501.00K	424.00K	477.00K	14.76M	20.99M
	Gross Profit
493.00K	501.00K	424.00K	477.00K	11.41M	19.60M
	EBIT
-37.70M	-39.81M	-29.26M	-34.30M	-68.03M	-113.47M
	EBITDA
-36.70M	-39.81M	-29.26M	-34.22M	-38.94M	-251.09M
	Net Income Common Stockholders
-33.98M	-39.83M	-28.45M	-33.95M	-73.33M	-255.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
136.25M	61.52M	93.25M	30.91M	42.25M	58.59M
	Total Assets
139.93M	66.91M	97.69M	40.76M	67.05M	93.74M
	Total Debt
0.00	99.00K	214.00K	-349.00K	349.00K	34.78M
	Net Debt
-49.51M	-19.83M	-30.41M	-31.26M	-41.90M	-22.78M
	Total Liabilities
9.55M	14.82M	8.95M	9.56M	18.41M	56.25M
	Stockholders Equity
130.38M	52.09M	88.73M	31.20M	48.64M	37.49M
Cash Flow		Free Cash Flow
-30.11M	-34.09M	-25.34M	-29.20M	-56.37M	-137.19M
	Operating Cash Flow
-30.11M	-33.97M	-25.34M	-29.20M	-56.37M	-137.08M
	Investing Cash Flow
-51.73M	23.36M	-57.35M	15.67M	1.03M	89.11M
	Financing Cash Flow
82.65M	-141.00K	82.39M	1.65M	39.78M	61.81M

VYNE Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Negative. The current price of 1.88 is below the 20-day moving average (MA) of 2.44, below the 50-day MA of 2.72, and below the 200-day MA of 2.35, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 26.71 is Positive, neither overbought nor oversold. The STOCH value of 3.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYNE.

VYNE Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	79 Outperform	$2.87B	12.64	38.89%	―	31.85%	―
BPMC	52 Neutral	$5.61B	―	-31.26%	―	104.04%	87.80%
CDTX	51 Neutral	$230.02M	―	-222.36%	―	-86.28%	-476.70%
ACRS	49 Neutral	$178.07M	―	-84.46%	―	-40.09%	-18.67%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
VYNE	44 Neutral	$28.59M	―	-56.54%	―	18.16%	86.65%
DERM	39 Underperform	$107.58M	―	-129.58%	―	-27.69%	-27.91%

VYNE Therapeutics Corporate Events

VYNE Therapeutics Sees Strong Shareholder Support for Growth

VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.